Analyst firms · UBS · SOLV
UBS SOLV price target and rating history
Solventum Corporation (SOLV) · Health Care
UBS rates Solventum Corporation (SOLV) Buy with a $95 price target, as of its latest action on Jul 28, 2026. It has published 3 rating actions on SOLV since October 2025, including 1 upgrade and 1 downgrade. Across 7 firms with a SOLV price target in the last 12 months, the median target is $95. UBS's target matches it.
- Current rating
- Buy
- Price target
- $95
- Median target, all firms
- $95
- Actions on SOLV
- 3
UBS price target on SOLV
Every UBS rating on SOLV
- Jul 28, 2026
- May 14, 2026
- Oct 1, 2025
How other firms rate SOLV
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $95 | Jul 28, 2026 |
| BMO Capital Markets | Market Perform | $81 | Jul 9, 2026 |
| Wedbush | Outperform | $94 | May 15, 2026 |
| Rothschild & Co Redburn | Sell | $60 | Mar 24, 2026 |
| KeyBanc Capital Markets | Overweight | $97 | Jan 26, 2026 |
| Mizuho | Outperform | $100 | Jan 20, 2026 |
| BTIG | Buy | $100 | Dec 2, 2025 |
Questions about UBS and SOLV
- What is UBS's price target for SOLV?
- UBS's latest stated price target for Solventum Corporation (SOLV) is $95, from its action on Jul 28, 2026.
- What is UBS's rating on SOLV?
- UBS rates SOLV Buy, a bullish rating, as of Jul 28, 2026.
- When did UBS last change its view on SOLV?
- On Jul 28, 2026, UBS upgrades to Buy from Neutral, price target $95.
- How does UBS's SOLV target compare with other analysts?
- Across 7 firms with a SOLV price target in the last 12 months, the median target is $95. UBS's target matches it.
All UBS ratingsSOLV news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.